Phase 3 clinical study in FSGS in the first half of 2021

There is serious value in DMX at current SP that the market is missing in my view.

Dimerix have repeatedly stated they are taking DMX200 into phase three trials and this looking increasingly likely to happen in 2021.

Costs are relatively low due to orphans designation so any CR will be small.

Chances of success for this drug type is 64%
https://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845

With the FSGS market value estimated at up to US$6.7B per year in the US alone, with DMX having exclusivity for ten years in US and 7 years in Europe. https://unauthorised investment advice/health/dimerix-is-tapping-a-potential-multi-billion-dollar-fsgs-market-opportunity/

So once the Phase 3 trial commences, there's a 64% chance DMX takes a drug to market with, lets say a potential A$20B per annum in global revenues?

There is a case for the market cap, right now, to be ten times what it is today. And it will still be a ten bagger on successful phase three results.

Time for the market to wake up.

(sorry title should read Phase 3 clinical study in FSGS in 2021, cant edit)